Efficacy and Safety of Jia Shen Tablets in Chronic Heart Failure
ConditionHeart Failure
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age40-79
SponsorTasly Pharmaceutical Group Co., Ltd
About this trial
Evaluate the efficacy and safety of Jia Shen Tablets in patients with Chronic Heart Failure.
Eligibility criteria
Qualifiers
Age 40-79 years, either sex;
Meet the diagnostic criteria for CHD and CHF;
Meet the TCM differentiation criteria of yang qi deficiency and blood stasis in CHF;
Class Ⅱ to Ⅲ for NYHA functional classification;
Disqualifiers
CHF with acute exacerbation or intravenous drug therapy;
Received cardiac resynchronization therapy (CRT) or other heart failure devices;
Within 3 months before randomization, acute coronary syndrome（ACS）, stroke or transient ischemic attack（TIA） occurred or received cardiac revascularization (PCI, CABG);
Plan to undergo cardiac revascularization (PCI, CABG) or cardiac resynchronization therapy (CRT) during the trial period;
Trial design
Treatments tested in this trial
- Jia Shen Tablet Placebo
- Low dose Jia Shen Tablet
- High dose Jia Shen Tablet
Treatment groups
288 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov